×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:VTGN

VistaGen Therapeutics (VTGN) Stock Forecast, Price & News

$1.06
+0.04 (+3.92%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.02
$1.14
50-Day Range
$1.02
$1.73
52-Week Range
$0.96
$3.55
Volume
1.93 million shs
Average Volume
1.39 million shs
Market Capitalization
$218.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.93
30 days | 90 days | 365 days | Advanced Chart
Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VistaGen Therapeutics logo

About VistaGen Therapeutics

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTGN
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.09 million
Book Value
$0.51 per share

Profitability

Net Income
$-17.93 million
Net Margins
-2,465.94%
Pretax Margin
-2,465.68%

Debt

Price-To-Earnings

Miscellaneous

Free Float
198,948,000
Market Cap
$218.92 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
5/29/2022
Next Earnings (Estimated)
7/05/2022
Fiscal Year End
3/31/2023

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

598th out of 1,429 stocks

Pharmaceutical Preparations Industry

271st out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

Is VistaGen Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics
or view top-rated stocks.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, July 5th 2022.
View our earnings forecast for VistaGen Therapeutics
.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.02. The business had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.33 million. VistaGen Therapeutics had a negative net margin of 2,465.94% and a negative trailing twelve-month return on equity of 44.10%. During the same quarter in the prior year, the company earned ($0.05) EPS.
View VistaGen Therapeutics' earnings history
.

What price target have analysts set for VTGN?

1 brokers have issued 1-year price objectives for VistaGen Therapeutics' stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate VistaGen Therapeutics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 749.1% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are VistaGen Therapeutics' key executives?
VistaGen Therapeutics' management team includes the following people:
  • Mr. Shawn K. Singh J.D., CEO & Director (Age 59, Pay $844.66k)
  • Dr. H. Ralph Snodgrass Ph.D., Founder, Pres & Chief Scientific Officer (Age 72, Pay $547.69k) (LinkedIn Profile)
  • Mr. Jerrold D. Dotson CPA, CPA, CFO, VP & Sec. (Age 69, Pay $484.62k)
  • Dr. Mark A. Smith M.D., Ph.D., Chief Medical Officer (Age 67, Pay $547.69k)
  • Ms. Ann Michelle Cunningham M.B.A., Chief Commercial Officer & Director (Age 54, Pay $30k)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 56)
  • Dr. Mark J. Ginski, Sr. VP and Head of Chemistry, Manufacturing & Controls (Age 50)
What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.68%), Nicholas Investment Partners LP (2.21%), State Street Corp (1.75%), Northern Trust Corp (0.79%), Ghost Tree Capital LLC (0.64%) and Renaissance Technologies LLC (0.57%). Company insiders that own VistaGen Therapeutics stock include H Ralph Snodgrass and Jerrold Duane Dotson.
View institutional ownership trends for VistaGen Therapeutics
.

Which institutional investors are selling VistaGen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Ghost Tree Capital LLC, Goldman Sachs Group Inc., Northern Trust Corp, BlackRock Inc., Bank of New York Mellon Corp, Principal Financial Group Inc., and ClariVest Asset Management LLC.
View insider buying and selling activity for VistaGen Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying VistaGen Therapeutics stock?

VTGN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nicholas Investment Partners LP, Epiq Partners LLC, XTX Topco Ltd, Nisa Investment Advisors LLC, SG Americas Securities LLC, GSA Capital Partners LLP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for VistaGen Therapeutics
or or view top insider-buying stocks.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $1.06.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics has a market capitalization of $218.92 million and generates $1.09 million in revenue each year. The company earns $-17.93 million in net income (profit) each year or ($0.360010) on an earnings per share basis.

How many employees does VistaGen Therapeutics have?

VistaGen Therapeutics employs 31 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 577-3600, via email at [email protected], or via fax at 888-482-2602.

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at con[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.